N-3C01 Monotherapy and Combination With PD-(L)1 Inhibitors in Advanced Solid Tumors

NCT07639450 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

114

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Malignant Solid Tumors

Interventions

DRUG: N-3C01(Q2W)
DRUG: N-3C01(Q3W)
DRUG: N-3C01
DRUG: Pembrolizumab

Sponsor

Hefei Xinzhu Biological Technology Co., Ltd.